At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30,804 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Non-interventional Observation Study for the Use of Palivizumab in High-risk Children in Germany- SYNAGIS
In Brief
An observational study for Respiratory Syncytial Virus Infections. Completed, enrolled 30,804 participants.
Detailed Summary
The SYNAGIS Registry was carried out in order to gather comprehensive real-world data on the use of palivizumab in children at high risk for serious respiratory syncytial virus (RSV) disease. This registry was designed as a post-marketing observational study, and conducted with the aim of collecting data on palivizumab administration, the risk factors for complicated RSV disease, frequency of hospitalizations, and drug adherence.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus Infections
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2002
First PostedJul 2010
Primary CompletionJul 2016
TodayJul 2026
First PostedJul 1, 2010
Enrollment StartSep 1, 2002
Primary CompletionJul 31, 2016
TodayJul 2, 2026
Enrollment to primary: 13.9 yearsPosted 16.0 years ago